AP NEWS

CLASS ACTION UPDATE for WBT, SOGO, IMMU and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

February 7, 2019

NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Welbilt, Inc. (NYSE: WBT) Class Period: February 24, 2017 - November 2, 2018 Lead Plaintiff Deadline: February 11, 2019 Join the action: https://www.zlk.com/pslra-1/welbilt-inc-loss-form?wire=3

Allegations: Welbilt, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the Company lacked effective internal control over financial reporting; (ii) the Company was incorrectly recording the tax basis of foreign subsidiaries and the amortization of their intangible assets; and (iii) as a result of the foregoing, Defendants’ statements about Welbilt’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. On November 5, 2018, Welbilt filed a Form 8-K for its Q3 2018, stating that “During the third quarter of 2018, the Company identified errors in the tax basis of a foreign subsidiary and incorrect amortization of the intangible assets held by the same entity… In addition, the Company discovered certain intercompany transactions were not recorded on a timely basis.” As a result of these errors, Welbilt announced that “the consolidated financial statements of the Company as of and for the year ended December 31, 2016 will be restated, and as of and for the years ended December 31, 2015 and 2017 are expected to be revised.”

To learn more about the Welbilt, Inc. class action contact jlevi@levikorsinsky.com.

Sogou Inc. (NYSE: SOGO) Class Period: Purchasers of American Depositary Shares pursuant and/or traceable to Sogou’s false and misleading Registration Statement and Prospectus issued in connection with the Company’s initial public offering on November 9, 2017 Lead Plaintiff Deadline: March 11, 2019 Join the action: https://www.zlk.com/pslra-1/sogou-inc-loss-form?wire=3

Allegations: During the class period, Sogou Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Chinese regulators were analyzing Sogou for regulatory action because of an increase in Sogou merchants’ sales of counterfeit goods; (ii) Chinese regulators were analyzing Sogou for regulatory action because Sogou’s existing software, advertising procedures, personnel, and audit procedures were insufficient to safeguard against compliance violations with governing Chinese regulations, and would need to be updated, enhanced, and strengthened, thus resulting in increased expenses; (iii) Sogou’s cost of revenues were skyrocketing primarily because of significant increases in Traffic Acquisition Cost, which is a primary driver of Sogou’s cost of revenues, as Sogou was dealing with significant price inflation from increased competition; (iv) Sogou was going to alter its strategy concerning smart hardware and push the Company’s AI capabilities to increase product competitiveness; (v) as a result of altering its smart hardware strategy, Sogou had already decided to phase out non-AI-enabled hardware products, such as legacy models of Teemo Smart Watch, and transition to use products integrating AI technologies, which Sogou hoped would reduce its hardware revenue in the second half of 2018; and (vi) as a result of the foregoing, Sogou’s public statements were materially false and misleading at all relevant times.

To learn more about the Sogou Inc. class action contact jlevi@levikorsinsky.com.

Immunomedics, Inc. (NASDAQ: IMMU) Class Period: August 23, 2018 - December 20, 2018 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3

The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food & Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.

To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.

Alkermes plc (NASDAQGS: ALKS) Class Period: February 17, 2017 - November 1, 2018 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/alkermes-plc-loss-form?wire=3

Allegations: Alkermes plc made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

To learn more about the Alkermes plc class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com

AP RADIO
Update hourly